Watch the webinar in full below
Are you considering taking your Life Sciences Business to the next level?
If yes, then this webinar, a collaboration with MHA, Baker Tilly and Freeths is for you.
If you have already secured early-stage funding and have completed some clinical trials that have shown promising results, this webinar will provide you with some additional and invaluable insights for planning for the next stage of development and commercialisation.
Like previous webinars in our Baker Tilly Going Global Life Sciences Series, MHA's Head of Life Sciences, Yogan Patel, will be posing a series of questions to an expert panel about the post-early-stage funding journey covering product development, and commercialisation including market access, IP protection, contracts and legal compliance. You will also get the opportunity to pose questions and participate.
Yogan A. Patel
Partner and Life Sciences Industry Lead at MHA
Yogan will lead the panel discussion, he heads up the Pharma, Life Science and Med-Tech sector for MHA.
Life Sciences Leader, Europe, Baker Tilly
Arun is a managing director with Baker Tilly in the healthcare and life sciences practice. He brings extensive knowledge in commercial and consulting delivery in Europe, the Middle East and Asia. He has more than two decades of commercial experience in analytics and strategy consulting with over a decade spent delivering solutions to healthcare and life sciences customers (commercial enablement, medical affairs, market access and regulatory affairs and compliance).
He has extensive consulting experience in healthcare analytics and AI strategy, digital and transformation programs as well as assisting life sciences companies in understanding the uptake of medicines, prescribing behaviours and delivering real-world insights around the unmet needs of patients.
Arun has led regional and global analytics go-to-market functions in scale-up to large, global life sciences organizations serving customers across Europe, the Middle East and Asia. Arun remains an active thought leader in digital analytics and its impact on healthcare and life sciences.
Corporate Finance Partner and Transaction Services Leader
Rob leads the Corporate Finance, Transaction Services team at MHA. Rob has over 15 years’ transaction consultancy experience, with considerable knowledge in global markets. He specialises in advising mid-market businesses, corporate clients and financial institutions, in their assessment of acquisitions and divestments, as well as assisting organisations on their journey to initial public offering. Rob’s primary focus is on providing financial due diligence services for M&A transactions. Rob has extensive deal experience across a variety of industry sectors, deal sizes and on a global basis.
Managing Director, Romilly Life Sciences
Peter has helped build multiple high-growth biomedical businesses, commercializing innovative products for surgery, diagnostics and digital treatment pathways in multiple international markets and leading R&D, regulated product development and strategic business development.
He founded Romilly Life Sciences to help health, tech and pharma organizations implement evidence-led digital product strategy, including technologies such as artificial intelligence, supported by effective cross-sector collaboration frameworks and coaching.
He is also co-founder of Migration Biotherapeutics, Honorary Professor at the University of Birmingham Centre for Regulatory Science and Innovation, Fellow and Chair of Healthcare at the Institution of Engineering and Technology, an Academy of Medical Sciences Future Leader in Innovation Enterprise and Research (FLIER) and works with HDRUK and NIHR to support leadership development and R&D funding programmes.
Claus is a partner in Freeths Life Sciences group. He specialises in all aspects of corporate and commercial work with a particular focus on mergers and acquisitions, shareholder agreements, joint ventures, licencing agreements and regulatory advice to companies and businesses in the Life Sciences and technology sector.
Claus has a wealth of experience in relation to inward investment, ie. overseas companies investing into the UK. Claus has advised a number of businesses from Scandinavia, Central and Western Europe, Asia and the US about investing in the UK and what such businesses should look out for in that process.
In addition to being a qualified solicitor in England and Wales, Claus is also qualified in Denmark, and Claus is admitted to the High Courts of Denmark and the Copenhagen Maritime and Commercial Court.